NATCO Pharma Limited (NATCOPHARM.BO)
INR 1475.25
(2.03%)
INR 1475.25
(2.03%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.71 Billion INR | 110.79% |
| 2022 | 1.76 Billion INR | -59.24% |
| 2021 | 4.32 Billion INR | 52.17% |
| 2020 | 2.83 Billion INR | -13.81% |
| 2019 | 3.29 Billion INR | -14.73% |
| 2018 | 3.86 Billion INR | 123.04% |
| 2017 | 1.73 Billion INR | -21.84% |
| 2016 | 2.21 Billion INR | 96.8% |
| 2015 | 1.12 Billion INR | -64.79% |
| 2014 | 3.19 Billion INR | 32.45% |
| 2013 | 2.41 Billion INR | -28.66% |
| 2012 | 3.38 Billion INR | 56.87% |
| 2011 | 2.15 Billion INR | 9.26% |
| 2010 | 1.97 Billion INR | 65.23% |
| 2009 | 1.19 Billion INR | -5.3% |
| 2008 | 1.26 Billion INR | 34.06% |
| 2007 | 941.33 Million INR | 23.15% |
| 2006 | 764.36 Million INR | -4.52% |
| 2005 | 800.52 Million INR | -28.03% |
| 2004 | 1.11 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 3.71 Billion INR | 110.79% |
| 2023 Q4 | 3.71 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 2.47 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 1.76 Billion INR | 0.0% |
| 2022 FY | 1.76 Billion INR | -59.24% |
| 2022 Q2 | 856 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 4.32 Billion INR | 52.17% |
| 2021 Q2 | 3.71 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 4.32 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 2.83 Billion INR | 0.0% |
| 2020 FY | 2.83 Billion INR | -13.81% |
| 2020 Q2 | 4.33 Billion INR | 0.0% |
| 2019 FY | 3.29 Billion INR | -14.73% |
| 2019 Q2 | 3.01 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 3.29 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 3.86 Billion INR | 0.0% |
| 2018 Q2 | 2.21 Billion INR | 0.0% |
| 2018 FY | 3.86 Billion INR | 123.04% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.94 Billion INR | 0.0% |
| 2017 Q4 | 1.73 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 1.73 Billion INR | -21.84% |
| 2016 Q2 | 1.6 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 2.21 Billion INR | 96.8% |
| 2016 Q4 | 2.21 Billion INR | 0.0% |
| 2015 Q2 | 1.12 Billion INR | 0.0% |
| 2015 FY | 1.12 Billion INR | -64.79% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 1.12 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q2 | 2.23 Billion INR | 0.0% |
| 2014 FY | 3.19 Billion INR | 32.45% |
| 2014 Q4 | 3.19 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 2.41 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 2.41 Billion INR | -28.66% |
| 2013 Q2 | 3.01 Billion INR | 0.0% |
| 2012 Q4 | 3.38 Billion INR | 0.0% |
| 2012 FY | 3.38 Billion INR | 56.87% |
| 2012 Q2 | 2.62 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 Q4 | 2.15 Billion INR | 0.0% |
| 2011 FY | 2.15 Billion INR | 9.26% |
| 2010 FY | 1.97 Billion INR | 65.23% |
| 2009 FY | 1.19 Billion INR | -5.3% |
| 2008 FY | 1.26 Billion INR | 34.06% |
| 2007 FY | 941.33 Million INR | 23.15% |
| 2006 FY | 764.36 Million INR | -4.52% |
| 2005 FY | 800.52 Million INR | -28.03% |
| 2004 FY | 1.11 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -952.154% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -21377.753% |
| Sigachi Industries Limited | 1.43 Billion INR | -159.487% |
| Bal Pharma Limited | 1.39 Billion INR | -165.81% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -2133.239% |
| Medico Remedies Limited | 80.5 Million INR | -4510.951% |
| Lasa Supergenerics Limited | 220.76 Million INR | -1581.449% |
| Venus Remedies Limited | 413.3 Million INR | -798.137% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -507.032% |
| Alpa Laboratories Limited | 52.46 Million INR | -6975.193% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 41.593% |
| Shilpa Medicare Limited | 9.37 Billion INR | 60.401% |
| Aarti Drugs Limited | 5.64 Billion INR | 34.216% |
| Lupin Limited | 29.21 Billion INR | 87.295% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 94.416% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 53.842% |
| Windlas Biotech Limited | 36.41 Million INR | -10095.001% |
| Suven Life Sciences Limited | 7.09 Million INR | -52203.79% |
| Eris Lifesciences Limited | 27.81 Billion INR | 86.654% |
| Valiant Laboratories Limited | 767.08 Million INR | -383.91% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 1.711% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 63.302% |
| Ipca Laboratories Limited | 14.38 Billion INR | 74.193% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -271.794% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 88.661% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -11.53% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | -79.174% |
| Laurus Labs Limited | 25.77 Billion INR | 85.598% |
| Piramal Pharma Limited | 47.1 Billion INR | 92.119% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -412.095% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 90.771% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 27.664% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 69.844% |
| Unichem Laboratories Limited | 2.47 Billion INR | -49.971% |
| Sequent Scientific Limited | 4.87 Billion INR | 23.887% |
| Novartis India Limited | 69.7 Million INR | -5225.681% |
| Wanbury Limited | 1.16 Billion INR | -218.669% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -471.109% |
| Wockhardt Limited | 23.56 Billion INR | 84.244% |
| Themis Medicare Limited | 957.92 Million INR | -287.505% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -4051.661% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 89.869% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -2064.684% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 81.459% |
| Divi's Laboratories Limited | 30 Million INR | -12273.333% |
| Gufic Biosciences Limited | 3.32 Billion INR | -11.5% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -1033.089% |
| Ind-Swift Limited | 10.13 Billion INR | 63.392% |
| Procter & Gamble Health Limited | 95.6 Million INR | -3782.845% |
| FDC Limited | 205.18 Million INR | -1709.099% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -91.905% |
| Granules India Limited | 13.15 Billion INR | 71.773% |
| Medicamen Biotech Limited | 308.17 Million INR | -1104.522% |
| Alkem Laboratories Limited | 14.18 Billion INR | 73.83% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -7972.724% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -84475.074% |
| Brooks Laboratories Limited | 56.41 Million INR | -6479.344% |
| Megasoft Limited | 1.47 Billion INR | -152.436% |
| ZIM Laboratories Limited | 1.08 Billion INR | -241.1% |
| Strides Pharma Science Limited | 25.16 Billion INR | 85.251% |
| Neuland Laboratories Limited | 953.89 Million INR | -289.141% |
| Morepen Laboratories Limited | 289.99 Million INR | -1180.035% |
| Hikal Limited | 8.17 Billion INR | 54.598% |
| Indoco Remedies Limited | 6.71 Billion INR | 44.759% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -30.131% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -1072.958% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -276.881% |
| Hester Biosciences Limited | 2.44 Billion INR | -51.896% |